clinical trial · NCT03815058
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
Genentech, Inc.·phase2·completed·n = 131
Advanced MelanomaAutogene cevumeranPembrolizumab
brief summary
This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.
started
Dec 21, 2018
primary completion
Jan 21, 2025
completion
Jan 21, 2025
last updated
Jan 30, 2026
official title
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced Melanoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol